Inari Medical is an Irvine, CA–based medical device company focused on catheter-based technologies to treat venous thromboembolism (VTE). The company has developed the FlowTriever and ClotTriever Systems, both designed to enable removal of large clot volumes from large vessels without the use of thrombolytic drugs. Both systems are 510(k) cleared by the U.S. FDA for thrombectomy in peripheral vessels and have received the CE mark. Led by President and CEO Bill Hoffman, Inari plans to commercialize its catheter-based technologies and continue advancing clinical and technology development programs. The company intends to deploy its new capital to support commercialization and ongoing development efforts. Inari Medical develops the FlowTriever Retrieval/Aspiration System, an FDA-cleared, catheter-based thrombectomy device designed to extract significant amounts of clot from large vessels. The company focuses on interventional treatment of vascular thrombus and emboli. Leadership includes Bill Hoffman (President and CEO) and Bob Rosenbluth (Chairman and Co-founder). Inari plans to use newly raised capital for product improvements and to fund clinical studies to demonstrate the FlowTriever's value across several markets. The financing demonstrates investor confidence from returning strategic backers. The company is based in Irvine, California. Inari Medical is the first company spun out of Inceptus Medical's incubator and focuses on developing and commercializing innovative devices for the interventional treatment of cardiovascular disease. The company will use the Series A proceeds to support product development, clinical evaluation and eventual product launch. Inari is led by Bob Rosenbluth, Brian Cox and Paul Lubock, who will lead initial development, clinical evaluation and product launch. The $4.7M Series A financing was completed through Inceptus Medical to provide the resources needed for these activities. Inceptus Medical is an Aliso Viejo, California–based medical device incubator founded in 2011 that provides engineering, clinical research expertise, leadership and financial resources to create and foster new companies. The financing is intended to advance Inari's initial development and pathways toward commercialization.

Total raised

$44M

Funding rounds

3

Latest round

Series C

Latest activity

Mar 2018